Calyxt Appoints CEO, Jim Blome, Former President & CEO of Bayer CropScience LP
September 18 2018 - 4:30PM
Business Wire
Regulatory News:
Calyxt, Inc. (NASDAQ:CLXT) and Cellectis S.A. (NASDAQ:CLLS –
EURONEXT GROWTH: ALCLS) announced today the appointment of James A.
Blome, former President and CEO of Bayer CropScience LP (North
America), as Chief Executive Officer of Calyxt, effective October
1, 2018. Jim Blome will work closely with Calyxt’s Board of
Directors to foster the development of the Company’s
consumer-focused products, including the upcoming commercial launch
of Calyxt’s first product, high-oleic soybean oil.
Jim Blome is a high-impact, global leader with over 25 years of
leadership experience in the agriculture industry, building teams
and strategies with consumer-focused cultures to better meet
consumer needs and maximize market share growth.
“We are extremely excited to have Jim Blome take the reins at
Calyxt, as this time represents a critical inflection point for the
Company, given that we expect our first healthy food product for
consumers will soon hit the market,” said Dr. André Choulika,
Chairman of Calyxt’s Board of Directors. “Having Jim join Calyxt is
a huge win for the entire Calyxt team as he is an experienced
global CEO and seasoned commercial executive with extensive
expertise in consumer-focused product development. He brings a
proven track record of global operational excellence. We look
forward to ushering in an exciting new chapter for Calyxt under
Jim’s leadership.”
“In addition, I would like to very warmly thank Dr. Yves Ribeill
for the fantastic job that he has done in a very short period of
time as interim CEO at Calyxt. Yves has taken significant steps to
position Calyxt on track for its first commercial launch. I
continue to be impressed by the way that he has been immediately
adopted by the team and motivated all to make Calyxt a great
success. Yves and Jim will work closely together on an efficient
transition. Yves will also remain a member of the Board of
Directors of the Company,” added Dr. André Choulika.
“I am honored to take on the role as Calyxt’s next CEO as the
Company has the potential to become the leader when it comes to
healthier food choices for consumers,” added Jim Blome. “I look
forward to working closely with the Board, management team and
talented and committed employees to leverage all of Calyxt’s truly
unique capabilities and deliver nutritionally rich, cost-effective
food products. I have made it my mission to always execute with
purpose, putting the consumer first in everything that we do.”
Jim Blome grew up on a family corn and soybean farm in Hubbard,
Iowa and a graduate of Iowa State University. Prior to joining
Calyxt, Jim was the President and CEO for Bayer CropScience LP
(North America). He held executive positions at Valent (Sumitomo
Chemical) and Agriliance LLC before joining Bayer.
Jim serves as the Chairman of CropLife America, Chairman of US
Farming and Ranching Foundation, the Independent, Non-Executive
Chairman of Concentric Ag Technologies, Inc. Jim is the 2013
recipient of the Henry A. Wallace Award from Iowa State University
for outstanding leadership and service to agriculture.
Kincannon & Reed, a leading executive search firm focused on
the food, agribusiness, and biosciences sectors, assisted Calyxt in
the recruitment of Jim Blome.
About Calyxt
Calyxt, Inc. is a consumer-centric, food- and
agriculture-focused company. Calyxt is pioneering a paradigm shift
to deliver healthier food ingredients, such as healthier oils and
high fiber wheat, for consumers and crop traits that benefit the
environment and reduce pesticide applications, such as disease
tolerance, for farmers. Calyxt develops non-transgenic crops
leveraging processes that occur in nature by combining its leading
gene-editing technology and technical expertise with its innovative
commercial strategy. Calyxt is located in Minneapolis-St. Paul, MN,
and is listed on the Nasdaq market (ticker: CLXT).
For further information please visit our website: www.calyxt.com
Calyxt™ and the corporate logo are trademarks owned by Calyxt,
Inc.
TALEN® is a registered trademark owned by Cellectis S.A.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. In some cases, you can
identify these statements by forward-looking words such as “may,”
“might,” “will,” “should,” “expects,” “plans,” “anticipates,”
“believes,” “estimates,” “predicts,” “potential” or “continue,” the
negative of these terms and other comparable terminology. These
forward-looking statements, which are subject to risks,
uncertainties and assumptions about us, may include projections of
our future financial performance, our anticipated growth strategies
and anticipated trends in our business. These statements are only
predictions based on our current expectations and projections about
future events. There are important factors that could cause our
actual results, level of activity, performance or achievements to
differ materially from the results, level of activity, performance
or achievements expressed or implied by the forward looking
statements, including those factors discussed under the caption
entitled “Risk Factors” in Calyxt’s Annual Report on Form 10-K, and
Cellectis’ Annual Report on Form 20-F and the financial report
(including the management report) for the year ended December 31,
2017 long with other Calyxt and Cellectis subsequent filings with
the U.S. Securities and Exchange Commission. We do not assume any
obligation to publicly provide revisions or updates to any forward
looking statements, whether as a result of new information, future
developments or otherwise, should circumstances change, except as
otherwise required by applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180918006074/en/
MediaJennifer Moore, VP CommunicationsPhone:
917-580-1088email: media@calyxt.comorCaitlin Kasunich / Nick
OpichKCSA Strategic Communications212.896.1241 / 212.896.1206email:
ckasunich@kcsa.com / nopich@kcsa.comorInvestor
RelationsSimon Harnest, VP Corporate Strategy and FinancePhone:
646-385-9008email: simon.harnest@calyxt.com
Calyxt (NASDAQ:CLXT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calyxt (NASDAQ:CLXT)
Historical Stock Chart
From Sep 2023 to Sep 2024